Drug intelligence / Profile preview

disodium hydrogen citrate

Development stage: Unknown
Lead developer: Stadmed
Modality: Small Molecules
Administration: Oral

Overview

Alkasol is an oral systemic and urinary alkalizer containing disodium hydrogen citrate as the active pharmaceutical ingredient. Developed and marketed by Stadmed Private Limited, it is primarily indicated for the treatment of urinary tract infections (UTIs), gout, and kidney stones (urolithiasis). The drug works by being metabolized into bicarbonate, which increases the pH of the blood and urine. This alkalinization helps in dissolving uric acid stones, preventing the formation of new stones, and mitigating the burning sensation associated with acidic urine in UTIs. It is also utilized in the management of metabolic acidosis associated with certain renal conditions.

Brand names: Alkasol
Other names: disodium hydrogen citratesodium acid citratedisodium citrate

Beyond the preview

Go deeper on disodium hydrogen citrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on disodium hydrogen citrate.

Explore the full profile